Table 7 Selected first-line results from phase 2 trials in BRAF mutant NSCLC
From: Oncogenic alterations in advanced NSCLC: a molecular super-highway
Trial | Clinical trials ID | Treatments | Objective response rate (%) | Median progression-free survival (months) | Median overall survival (months) |
|---|---|---|---|---|---|
Planchard et al | NCT01336634 | Dabrafenib/trametinib | 64 | 14.6 | 24.6 |
PHAROS | NCT03915951 | Encorafenib/ binimetinib | 75 | NR | NR |